AstraZeneca is buying Fusion Pharmaceuticals, a Canadian company specializing in radioconjugation cancer treatments, for $2.4 billion.
Petru Nicolaescu
Health
Unsplash.com
Always see our news on Google
The acquisition of Fusion Pharmaceuticals by AstraZeneca brings innovative new treatments to the company's portfolio. Radioconjugates developed by Fusion are an alternative to chemotherapy and radiotherapy, minimizing damage to healthy cells. The most advanced treatment, FPI-2265, is for patients with metastatic prostate cancer.
Latest News
11:02
Iranian authorities report fires aboard two tankers and a tug in the Strait of Hormuz
10:50
Kaja Kallas calls on the new US Congress to support Ukraine and increase pressure on Russia
10:50
American bases in Romania, possible targets for Iran in the event of a new war, according to the hardline Iranian publication “Kayhan” / Other American facilities in Europe were also mentioned
10:48
DIICOT has dismantled a network coordinated by the Burtea clan, suspected of sexually exploiting 30 young women in Europe
10:42
Police in Caracal are investigating a possible attempted abduction involving an 11-year-old child
See more news
NEWS ON THE SAME TOPICS
IT&C knowledge
Novo collaborates with Anthropic to use artificial intelligence in the research and development of new medicines
International
An experimental cancer vaccine, developed by Moderna and Merck, has shown promising results in patients with melanoma.
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
 (1).webp)
.webp)
